(19)
(11) EP 1 423 391 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.12.2007 Bulletin 2007/50

(45) Mention of the grant of the patent:
17.05.2006 Bulletin 2006/20

(21) Application number: 02797553.1

(22) Date of filing: 29.08.2002
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61K 31/529(2006.01)
A61P 29/00(2006.01)
 C07D 473/00(2006.01)
A61K 31/52(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/EP2002/009663
(87) International publication number:
WO 2003/020721 (13.03.2003 Gazette 2003/11)

(54)

PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES

PYRROLOPYRIMIDINE ALS MITTEL ZUR INHIBIERUNG VON CYSTEINPROTEASEN

PYRROLOPYRIMIDES EN TANT QU'AGENTS D'INHIBITION DE CYSTEINE PROTEASES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
RO SI

(30) Priority: 30.08.2001 GB 0121033

(43) Date of publication of application:
02.06.2004 Bulletin 2004/23

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR 
  • Novartis Pharma GmbH
    1235 Vienna (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • BETSCHART, Claudia
    CH-4054 Basel (CH)
  • HAYAKAWA, Kenji
    Hyogo Pref. 665-0871 (JP)
  • IRIE, Osamu
    Tsukuba-shi, Ibaraki Pref. 300-3253 (JP)
  • SAKAKI, Junichi
    Ibaraki Pref. 305-0051 (JP)
  • IWASAKI, Genji
    Ibaraki Pref. 305-0046 (JP)
  • LATTMANN, René
    CH-4102 Binningen (CH)
  • MISSBACH, Martin
    CH-5073 Gipf-Oberfrick (CH)
  • TENO, Naoki
    Ushiku, Ibaraki Pref.300-1232 (JP)

(74) Representative: de Weerd, Petrus G.W. et al
Novartis International AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
WO-A-00/00201
US-A- 5 683 999
 WO-A-01/70743
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).